Company Description
Orthofix Medical Inc. operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally.
It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.
This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations.
The Global Orthopedics segment offers products and solutions that allow physicians to treat various orthopedic conditions related to limb reconstruction and deformity correction unrelated to the spine.
This segment designs, develops, and markets external and internal fixation orthopedic products that are coupled with enabling digital technologies to serve the complete patient treatment pathway.
It sells its products through distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers.
The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018.
Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
| Country | United States |
| Founded | 1987 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 1,634 |
| CEO | Massimo Calafiore |
Contact Details
Address: 3451 Plano Parkway Lewisville, Texas 75056 United States | |
| Phone | 214 937 2000 |
| Website | orthofix.com |
Stock Details
| Ticker Symbol | OFIX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000884624 |
| CUSIP Number | 68752M108 |
| ISIN Number | US68752M1080 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Massimo Calafiore | President, Chief Executive Officer, Director and Interim President of Global Spine |
| Geoffrey C. Gillespie | Vice President and Corporate Controller |
| Julie B. Andrews | Chief Financial Officer |
| Aviva McPherron | President of Global Operations and Quality |
| Julie D. Dewey | Chief Investor Relations and Communications Officer |
| Jill Mason | Interim Chief Ethics and Compliance Officer and Vice President of Corporate Counsel |
| J. Andres Cedron | Chief Legal Officer and Corporate Secretary |
| Stephanie Walsh | Chief Human Resources Officer |
| Ehab M. Esmail | Senior Vice President of Global Quality, Regulatory and Clinical Affairs |
| Tyler P. Lipschultz | President of Global Biologics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | 8-K | Current Report |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Aug 15, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 15, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 6, 2024 | 10-Q | Quarterly Report |
| Aug 6, 2024 | 8-K | Current Report |